The claim

““Pfizer is ending development of its once-daily weight-loss pill danuglipron because a participant suffered liver injury.””

Pfizer did discontinue development of its once-daily danuglipron pill after elevated liver enzymes were observed in a trial participant, but the company said the issue resolved after stopping the drug and did not describe it as severe liver failure.

Multiple reputable outlets reported that Pfizer stopped development of its once-daily oral GLP-1 candidate danuglipron after a clinical-trial participant experienced elevated liver enzymes consistent with liver injury. Pfizer publicly stated the finding was observed in a participant who was asymptomatic and that the lab abnormality resolved after discontinuation, which is important context because “liver injury” in this setting typically refers to biomarker elevations rather than confirmed permanent damage. The decision was also framed in the context of overall risk/benefit and the competitive GLP-1 landscape, not solely one event. The viral claim is broadly accurate about the discontinuation being tied to a liver-safety signal, but it can be misleading if interpreted as Pfizer confirming severe, irreversible liver damage in a participant.